Orforglipron, developed by Eli Lilly, is the first non-peptide oral GLP-1 agonist, achieving up to 1.8% HbA1c reduction and 1012% body-weight loss in Phase 3 trials
It does not mean the finished product has been studied, and it does not mean it will produce the same outcomes described in the referenced studies
Over nine weeks they found that the participants still drank, but they drank less, had fewer cravings, and experienced fewer days of heavy drinking compared to those who took the placebo
Naltrexonebupropion for managing overweight and obesity (TA494)
Weight Loss Medications Prescribed at Klinic At our Grand Junction clinic, Klinic prescribes only FDA-approved branded medications, ensuring quality, consistency, and safety
Barrett-Baas ensures that each session is performed with the highest level of care and attention to safety